SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is actively trending as its 'move-to-earn' model sparks ongoing debate within the crypto community. Many holders express optimism for a future rebound and are accumulating tokens despite a currently low valuation, while others remain skeptical of its long-term viability.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as its amended offer for Warner Bros. Discovery, including additional financial protections and a focus on regulatory certainty, has prompted WBD to reopen deal talks despite prior support for a rival bid. Community discussion centers on whether this will lead to PSKY acquiring WBD, given ongoing antitrust scrutiny on the competitor's proposal and the potential significant debt impact on PSKY.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL (GRAL) is trending amid a sharp stock drop following news that its NHS-Galleri cancer screening trial missed a primary endpoint, sparking bearish concerns about its future. However, many investors view this as an overreaction, pointing to strong cash reserves, positive data from other studies like PATHFINDER 2, and continued momentum for FDA approval and US commercial adoption of its multi-cancer early detection test.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following a significant stock drop sparked by its Q4 earnings, which revealed a net loss and weak guidance, intensifying community debate over the 'Buy Now, Pay Later' model's sustainability and the company's valuation after its already steep post-IPO decline.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

Satoshi Crypto ($SATOSHI) is trending as its community passionately embraces it as the ultimate tokenization of Satoshi Nakamoto, the legendary architect of Bitcoin. The token is gaining significant attention for its limited 2.1 million supply and its strong narrative as the definitive origin story and culture of the entire crypto industry.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending following its strong Q4 earnings beat and record free cash flow, but a lowered 2026 gold production outlook and higher projected costs have sparked a mixed market reaction. The community is actively debating if the subsequent dip presents a buying opportunity, especially as gold prices remain robust, or if the guidance signals prolonged operational challenges.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics (CADL) is experiencing intense debate after announcing both a public stock offering at $5.45 and a $100 million royalty funding agreement with RTW Investments tied to the FDA approval of its prostate cancer therapy. While some investors express concern over immediate share dilution, others view the strategic financing, especially from a biotech-focused fund like RTW, as a critical validation and necessary step to bolster its cash position for advancing its promising pipeline and BLA submission.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending due to an S-1 filing for a Grayscale Trust and its deepening integration into the AI sector through NVIDIA's program, with the community highly engaged in discussions around its chain abstraction technology for seamless cross-chain interoperability and long-term potential.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is significantly trending as its AI chip unit, Kunlunxin, confidentially filed for a Hong Kong IPO, poised to unlock substantial value, while the company also announced a new $5 billion share buyback and its first-ever dividend policy, signaling strong commitment to shareholder returns and fueling community discussion on its AI and autonomous driving leadership.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed as investors assess the recent acquisition of Astria Therapeutics, which brings the promising, long-acting HAE therapy Navenibart into its pipeline, with new clinical data expected at an upcoming medical conference. Despite strong operational performance and growing Orladeyo sales, the community expresses frustration over the stock's persistent undervaluation and significant short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altimmune (ALT) Expected to Announce Quarterly Earnings on Thursday

Altimmune (NASDAQ:ALT) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the ten brokerages that are presently covering the stock, Marketbeat.com reports...

Altimmune (NASDAQ:ALT) Trading Up 7.2% - Here's What Happened

Altimmune (NASDAQ:ALT) Trading 7.2% Higher - Should You Buy...

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration PR Newswire VANCOUVER...

Altimmune (NASDAQ:ALT) Rating Increased to Strong-Buy at Barclays

Barclays raised shares of Altimmune to a "strong-buy" rating in a research report on Tuesday...

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million registered direct offering of common stock.read more...

Altimmune (NASDAQ:ALT) Shares Gap Down - Here's Why

Altimmune (NASDAQ:ALT) Shares Gap Down - Time to Sell...

<ul class="summary-bullets"><li>Wall Street remains positive ahead of the Federal Reserve’s policy decision and a slate of megacap tech earnings.</li><li>The Fed is expected to hold rates steady, but investors will be watching for Chair Jerome Powell’s press conference for clues on the longer-term rate path.</li><li>China has reportedly approved the first batch of Nvidia’s H200 AI chips for import.</li></ul>U.S. stock futures were higher early Wednesday as traders geared up for the Federal Reserve’s first policy decision of the year, as well as the first of the Magnificent Seven earnings today. Meta (META), Microsoft (MSFT), and Tesla (TSLA) are all scheduled to report results after the bell.The Fed is expected to hold interest rates steady. Investors will be watching for Chair Jerome Powell’s 2:30 PM ET press conference for policy clues for the year ahead.&nbsp;As of 3:00 a.m. ET on Wednesday, Nasdaq futures were up 0.9%, S&amp;P 500 futures and Russell 2000 futures were up 0.3%. However, the Dow futures were flat with a positive bias.&nbsp;&nbsp;Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, slipped to ‘extremely bearish’ from 'bearish’ a day ago, amid high message volumes. Both were among the top trending tickers on Stocktwits at the time of writing.&nbsp;And there’s no stopping the precious metals rally. Both gold and silver notched fresh records, with gold surging past $5200 and silver past $114.&nbsp;<a href="https://stocktwits.com/symbol/GLD/">SPDR Gold Shares ETF (GLD)</a> was among the top trending tickers on Stocktwits at the time of writing. The&nbsp;<a href="https://stocktwits.com/symbol/SLV">iShares Silver Trust (SLV)</a> also saw retail sentiment in ‘extremely bullish’ territory over the past day, with ‘extremely high’ levels of chatter.Trending Stocks To WatchNvidia (NVDA):&nbsp;China has reportedly approved the first batch of H200 AI chips for imports. This follows Jensen Huang’s visit to the region this week.&nbsp;Meta Platforms (META), Microsoft (MSFT), Tesla (TSLA), IBM (IBM): The earnings print will test whether AI infrastructure spending is generating sustainable bottom-line growth. Meanwhile, Tesla reportedly saw its new-car registrations in Europe drop 20% in December.ASML (ASML):&nbsp;Reported record Q4 bookings, doubling analyst estimates on massive AI demand.Amazon (AMZN):&nbsp;Reportedly sent an internal notice referencing ‘organizational changes,’ with expectations of further layoffs possibly emerging this week.C3.ai (AI):&nbsp;The company is reportedly in talks to be acquired by Automation Anywhere.Energy Fuels (UUUU): Roth Capital upgraded the stock to Neutral from Sell, citing supportive uranium pricing. They also upped the&nbsp;price target to $15.50 from $13. Altimmune (ALT): The company is raising $75 million by selling new shares directly to investors and plans to use the funds to pay for the upcoming Phase 3 trial of its drug for MASH (a type of chronic liver disease).Other tickers trending on Stocktwits at the time of writing included UnitedHealth Group (UNH), Richtech Robotics (RR), CoreWeave (CRWV), Movano (MOVE), among others.&nbsp; Other Catalysts To Watch On the economic front, beyond the 2:00 pm ET FOMC Decision, traders will monitor U.S. MBA Mortgage Applications and a tentative speech by President Trump this morning.&nbsp;And on the earnings radar, investors will also be watching for the quarterly reports from Starbucks (SBUX), AT&amp;T (T), GE Vernova (GEV), and General Dynamics (GD) before the markets open. Meanwhile, other than the big three (MSFT, META, TSLA),&nbsp; ServiceNow (NOW), and Wolfspeed (WOLF),&nbsp;among others, report later today.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today

Retail sentiment on major ETFs such as SPY and QQQ turned ‘extremely bearish’ on Stocktwits. 

Equity

Retail sentiment on major ETFs such as SPY and QQQ turned ‘extremely bearish’ on Stocktwits. 


In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon

Altimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk.

Altimmune (NASDAQ:ALT) Trading 16.1% Higher - Should You Buy?

Altimmune (NASDAQ:ALT) Trading Up 16.1% - Should You Buy...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

The FDA's new guidance to accept a single pivotal Phase 3 trial instead of two could significantly accelerate Pemvidutide's path to market and reduce development costs.

Speculation intensifies around a potential partnership or acquisition, fueled by Pemvidutide's strong profile and recent institutional activity.

Traders are actively "bottom fishing" and observing significant dark pool volume, signaling a potential accumulation phase by institutional investors at current low prices.

CEO Jerry Durso faces intense criticism from shareholders for the stock's performance, lack of transparency, and perceived inaction to boost shareholder value.

After a prolonged red streak, investors are eagerly watching for a green closing day, hoping it signals a reversal and the end of the stock's recent downtrend.

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALT News

ALTAltimmune Inc